{"id":201602,"name":"ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)","slug":"zyla-life-sciences-fka-egalet-corporation","state":"PA","country":"United States of America","description":"Registrant's name change from Egalet Corporation to Zyla Life Sciences","totalSpending":515316.38,"filings":9,"yearlySpending":[{"year":2018,"income":515316.38},{"year":2019,"income":0}],"issues":[{"code":"MMM","display":"Medicare/Medicaid"},{"code":"HCR","display":"Health Issues"},{"code":"ALC","display":"Alcohol and Drug Abuse"}],"firms":["ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)"],"lobbyists":["CARA MOON","EILEEN BLAIR CLARK-SCHOEB"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement\nProvisions related to abuse-deterrent opioid coverage and access in Medicare","Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Co","S. 524 (114th Congress): Provisions related to opioid treatment and abuse","Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Co","Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement\nProvisions related to abuse-deterrent opioid coverage and access in Medicare\nH.R. 5582, the Abuse"]}